TLDR
- The FDA issued a Complete Response Letter for ivonescimab in EGFR-mutated lung cancer.
- SMMT fell about 17% in premarket trading to near $11.70.
- The agency wants a statistically significant overall survival gain.
- Jefferies sees limited downside, while Barclays cut its target to $18.
- Summit says its commitment to ivonescimab is unchanged.
Summit Therapeutics (SMMT) stock dropped about 17% in premarket trading on Monday, landing near $11.70. That puts it at a new 52-week low.
Summit Therapeutics Inc., SMMT
The trigger came on Sunday, when the FDA sent a Complete Response Letter on the company’s drug application. The letter says ivonescimab cannot be approved in its current form.
The application covered ivonescimab paired with platinum-containing chemotherapy. It targets locally advanced or metastatic non-small cell lung cancer in patients who already tried an EGFR tyrosine kinase inhibitor.
The stock had climbed as high as $29.23 over the past year. It now sits close to the bottom of that range, around $12.07.
What the FDA Said
The agency ruled that Summit did not show substantial evidence of effectiveness. The missing piece was a statistically significant improvement in overall survival.
Progression-free survival gains alone were not enough, the FDA said. It wants the survival data to back up the benefit-risk case.
The Phase 3 HARMONi trial did hit its progression-free survival goal. The overall survival result, however, fell short of statistical significance.
Summit pointed out that the combination still showed a positive overall survival trend. It also noted that no approved regimen in this setting has shown a statistically significant survival benefit.
A later analysis with longer follow-up of Western patients gave a hazard ratio of 0.76. That figure held across the full group, Asian patients and Western patients.
The safety profile was described as manageable. There were no new safety signals, and discontinuation and death rates were similar across both trial arms.
Analysts and Partners React
Jefferies called the rejection the base case for investors. The firm sees limited downside because second-line EGFR was never central to the investment story.
Jefferies also said Summit had earlier shared that it was not aligned with the FDA on this filing. Its eyes are now on HARMONi-3 squamous progression-free survival data, expected around the end of 2026.
Barclays kept its Equalweight rating on the stock. It trimmed its price target to $18 from $20.
Akeso, Summit’s partner, issued a notice on Monday about abnormal stock price swings. That came after Summit’s press release on Sunday.
The wider market offered no cushion. The Nasdaq closed down 0.91% on Friday, and tech weakness carried into the new week.
No regulator in Summit’s license territories, including the U.S. and Europe, has approved ivonescimab. China approved the drug in May 2024.
Summit says its plans are unchanged. It cited five positive Phase III studies across Summit and Akeso.







